Actively Recruiting
Evaluation of TSND-201 Capsules Versus Placebo for Treating PTSD in Adults A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Assessing Safety and Efficacy
Led by Transcend Therapeutics · Updated on 2026-11-03
300
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial involves participants who have experienced PTSD symptoms for at least six months and have previously tried pharmacological or trauma-focused psychotherapy treatments. The study aims to assess how different doses of TSND-201 compare to a placebo in managing PTSD symptoms. Participants will be randomly assigned to one of three groups two groups receiving different doses of TSND-201 capsules, and one group receiving placebo capsules. These capsules are taken orally once a week for four consecutive weeks during the Treatment Period. After completing this period, participants will enter an 8-week Follow-up Period to monitor their progress and any lasting effects. Throughout the study, participants will undergo evaluations including the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD severity. Researchers will monitor safety and efficacy over up to 12 weeks. The study includes regular assessments and questionnaires to track symptoms and wellbeing during and after treatment.
CONDITIONS
Brief Title
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here